Identification of SER-PRO-CYS Peptide in Blood Serum of Multiple Sclerosis Patients

Myronovkij, Severyn; Negrych, N.O.; Nehrych, Tetyana; Ткаченко, В. М.; Souchelnytskyi, Serhiy; Stoika, Rostyslav; Kit, Yu. Ya.

doi:10.2174/0929866523666160622215628

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ser-Pro-Cys (SPC) tripeptide was first detected by us in the blood serum of multiple sclerosis patients. 1 However, up to now its biological role remained unknown. In this study, we addressed this issue in more detail.…”

Section: Resultsmentioning

confidence: 99%

“…7 We first detected and isolated previously unknown Ser-Pro-Cys (SPC) tripeptides in blood serum of the multiple sclerosis patients. 1 However, the origin and biological activity of this peptide remained unknown. Here, we covalently conjugated the SPC tripeptide with the PEGylated comb-like polymer (see Experimental Section).…”

Section: ■ Introductionmentioning

confidence: 99%

“…The development of novel multifunctional nanomedicines with enhanced anticancer action, reduced negative side effects, and improved physical-chemical characteristics providing water solubility to poorly soluble anticancer drugs is an important trend in the modern pharmaceutic industry. ,,− Natural and synthetic polymers are the most popular nanocarriers applied for delivery of the anticancer drugs, including water insoluble ones. Such nanocarriers can also secure targeted delivery and stimuli-responsive action of anticancer drugs, as well as a possibility for circumventing an acquired drug resistance .…”

Section: Introductionmentioning

confidence: 99%

“…We first detected and isolated previously unknown Ser-Pro-Cys (SPC) tripeptides in blood serum of the multiple sclerosis patients . However, the origin and biological activity of this peptide remained unknown.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Covalent Conjugate of Ser-Pro-Cys Tripeptide with PEGylated Comb-Like Polymer as Novel Killer of Human Tumor Cells

et al. 2022

Self Cite

View full text Add to dashboard Cite

Recently, we detected a previously unknown Ser-Pro-Cys (SPC) tripeptide in the blood serum of multiple sclerosis patients. Its role as a biomarker of the autoimmune disease was suggested, although its origin and real biological activity remained unclear. Here, we created a biocompatible PEGylated comb-like polymer that was used as a platform for covalent immobilization of the SPC, which provided a possibility to explore the biological activity of this tripeptide. This macromolecular conjugate was synthesized via a reaction of the terminal epoxide group of the biocompatible copolymer of dimethyl maleate (DMM) and polyethylene glycol methyl ether methacrylate (PEGMA) with the amino group of the SPC tripeptide. Unexpectedly, the resulting conjugate containing SPC demonstrated anticancer activity in vitro. It possessed pro-apoptotic action toward human tumor cells, while there was no cytotoxic effect of that conjugate toward normal lymphocytes of human peripheral blood. The detected biological effects of the created conjugate inspired us to carry out a thorough study of structural and colloidal-chemical characteristics of this surface-active copolymer containing side PEG chains and a terminal nontoxic synthetic fragment. The copolymer composition, in particular, the content of the peptide fragment, was determined via elemental analysis and NMR spectroscopy. At CMC, it formed polymeric micelle-like structures with a hydrodynamic diameter of 180 ± 60 nm. The conjugation of the peptide fragment to the initial comb-like copolymer caused a change of zeta-potential of the formed micelle-like structures from −0.15 to 0.32 mV. Additional structural modification of the created polymeric nanoplatform was performed via attachment of fluorescein isothiocianate (FITC) dye that permitted monitoring of the behavior of the bioactive SPC-functionalized conjugate in the treated tumor cells. Its penetration into those cells and localization in their cytoplasm were revealed. The principal novelty of this study consists in finding that covalent conjugation of two nontoxic compoundsSPC tripeptide and comb-like PEGylated polymerled to an unexpected synergy which appeared in the distinct cytotoxic action of the macromolecular complex toward human tumor cells. A potential role of peculiarities of the colloidal-chemical properties of the novel conjugate in its cytotoxic effect are discussed. Thus, synthesized comb-like PEGylated polymers can provide a prospective nanoplatform for drug delivery in anticancer chemotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: ■ Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Covalent Conjugate of Ser-Pro-Cys Tripeptide with PEGylated Comb-Like Polymer as Novel Killer of Human Tumor Cells

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Human urine has a potential non-invasive diagnos tic value [1]. Earlier, we used the method of isolation of TCA-soluble compounds in human blood serum and identified a novel 48 kDa Myo 1c protein [4,5] and Ser-Pro-Cys peptide (prosercyn) as protein biomarkers of the multiple sclerosis [12].…”

mentioning

confidence: 99%

Identification of cortactin molecular forms in human urine and their possible diagnostic value

Starykovych¹,

Souchelnytskyi²,

Fayura³

et al. 2021

Ukr.Biochem.J

View full text Add to dashboard Cite

Background and roles: myosin in autoimmune diseases

Fu,

Zou,

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The myosin superfamily is a group of molecular motors. Autoimmune diseases are characterized by dysregulation or deficiency of the immune tolerance mechanism, resulting in an immune response to the human body itself. The link between myosin and autoimmune diseases is much more complex than scientists had hoped. Myosin itself immunization can induce experimental autoimmune diseases of animals, and myosins were abnormally expressed in a number of autoimmune diseases. Additionally, myosin takes part in the pathological process of multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, autoimmune myocarditis, myositis, hemopathy, inclusion body diseases, etc. However, research on myosin and its involvement in the occurrence and development of diseases is still in its infancy, and the underlying pathological mechanisms are not well understood. We can reasonably predict that myosin might play a role in new treatments of autoimmune diseases.

show abstract

Identification of SER-PRO-CYS Peptide in Blood Serum of Multiple Sclerosis Patients

Cited by 3 publications

References 0 publications

Covalent Conjugate of Ser-Pro-Cys Tripeptide with PEGylated Comb-Like Polymer as Novel Killer of Human Tumor Cells

Covalent Conjugate of Ser-Pro-Cys Tripeptide with PEGylated Comb-Like Polymer as Novel Killer of Human Tumor Cells

Identification of cortactin molecular forms in human urine and their possible diagnostic value

Background and roles: myosin in autoimmune diseases

Contact Info

Product

Resources

About